Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CureVac N.V (CVAC) Short-term Investments: 2019-2025

Historic Short-term Investments for CureVac N.V (CVAC) over the last 4 years, with Jun 2025 value amounting to $3.5 million.

  • CureVac N.V's Short-term Investments fell 12.45% to $3.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $3.5 million, marking a year-over-year decrease of 12.45%. This contributed to the annual value of $3.9 million for FY2024, which is 35.19% up from last year.
  • Per CureVac N.V's latest filing, its Short-term Investments stood at $3.5 million for Q2 2025, which was down 10.87% from $4.0 million recorded in Q1 2025.
  • CureVac N.V's 5-year Short-term Investments high stood at $48.3 million for Q2 2021, and its period low was $2.6 million during Q3 2022.
  • Moreover, its 3-year median value for Short-term Investments was $3.9 million (2024), whereas its average is $4.0 million.
  • Per our database at Business Quant, CureVac N.V's Short-term Investments spiked by 689,537.91% in 2021 and then slumped by 92.03% in 2022.
  • CureVac N.V's Short-term Investments (Quarterly) stood at $5.3 million in 2021, then declined by 13.90% to $4.6 million in 2022, then tumbled by 37.46% to $2.9 million in 2023, then soared by 35.19% to $3.9 million in 2024, then decreased by 12.45% to $3.5 million in 2025.
  • Its Short-term Investments was $3.5 million in Q2 2025, compared to $4.0 million in Q1 2025 and $3.9 million in Q4 2024.